John Litchfield - Concepedia

Author

John Litchfield

Also Known As

G. Cavaletti, J. E. Litchfield, J. Litchfield, J.E. Litchfield, JOHN LITCHFIELD, Jean-Louis Kirouac, John E Litchfield, John E. Litchfield, John Litchfield, Litchfield, J.

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of South Carolina Purdue University West Lafayette

About

John Litchfield is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	670
2	Health Sciences	5	5	204
3	Natural Sciences	5	5	145
4	Engineering	2	2	94
5	Allergy	1	1	17

John Litchfield

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Identification of Glyoxal and Arabinose as Intermediates in the Autoxidative Modification of Proteins by Glucose Kevin J. Wells‐Knecht, David V. Zyzak, John Litchfield, Biochemistry	1995	588
Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions Manthena V. S. Varma, Yurong Lai, Bo Feng, Pharmaceutical Research Pharmacokinetic ModelingHepatologyMedicineLiver PhysiologyPhysiology	2012	128
Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach Sumathy Mathialagan, Mary Piotrowski, David A. Tess, Drug Metabolism and Disposition	2017	127
pH-Sensitive Interaction of HMG-CoA Reductase Inhibitors (Statins) with Organic Anion Transporting Polypeptide 2B1 Manthena V. S. Varma, Charles J. Rotter, Kevin M. Whalen, Molecular Pharmaceutics	2011	117
Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield, Journal of Medicinal Chemistry	2011	114
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1 Robert L. Dow, Jiancheng Li, Michael P. Pence, ACS Medicinal Chemistry Letters Pharmaceutical SciencePharmacotherapyPharmaceutical ChemistryInsulin SignalingMetabolic Syndrome	2011	100
Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle Jeffrey A. Pfefferkorn, Jihong Lou, Martha L. Minich, Bioorganic & Medicinal Chemistry Letters Unique Metabolic LiabilityBiochemistryMedicineMechanism Of ActionGlucokinase Activators	2009	80
AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats Shengzu Yang, John Litchfield, John Baynes Archives of Biochemistry and Biophysics BiochemistryMedicineMaillard CrosslinksDiabetesGlycobiology	2003	77
Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion Manthena V. S. Varma, George Chang, Yurong Lai, Drug Metabolism and Disposition	2012	70
Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates, MedChemComm	2011	68

Page 1